EW P/FCF 35.7 | Overview

EW

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$47.68B

Industry

Health Care

EPS (TTM)

$1.84

P/E (TTM)

44.42

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

7.86

P/B

4.61

Diluted Shares

580.60M

Ex-Dividend

--

Next Earnings

04-21

Forward P/E

26.92

Payout Ratio

--

P/FCF (TTM)

35.72

FCF Yield

2.80%

Earnings Yield

2.25%

52 Week Range

Score Card

Explore Scores Tab

3.60

Good

Edwards Lifesciences Corp has grown revenue at 10.86% over the past year, which is strong growth. Also, it has more cash than liabilities meaning it could use its current cash position to be completely debt-free, if it wanted to.

Valuation Model

Key Score

5.00

Very Good

Management

4.00

Good

Growth

1.00

Very Bad

Profitability

2.00

Bad

Fin. Health

5.00

Very Good

Dividends

--

Analyst

1.00

Very Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

5 new filings were in the last 7 days

Filter Form Types

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-26 18:04:17

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-03-26 16:07:42

Form ARS

Unknown Form Type

Filed on 2026-03-26 16:07:14

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-03-26 16:06:11

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-03-26 16:05:48

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-11 17:15:11

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-11 17:10:00

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-11 16:05:26

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-11 16:02:57

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-02 17:50:44

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-26 19:33:53

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-02-26 16:08:19

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-02-21

High:

$115.50

40.7%

Avg:

$97.45

18.7%

Low:

$72.72

-11.4%

(% change is relative to the current stock price: $82.10)

Analyst Recommendations

Go to Analyst Tab

3.98

Good

26%

Strong Buy (11)

47%

Buy (20)

28%

Hold (12)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://www.edwards.com
Address
One Edwards Way, Irvine CALIFORNIA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1099800

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 16,000 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

IPO Date

2000-03-27

Industry

Health Care

Total Employees

16,000

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Health Care Equipment & Supplies

GICS Sub

Health Care Equipment

GICS Sector

Health Care

GICS Group

Health Care Equipment & Services

Switch to Dark

Pricing

Learn

EW - Edwards Lifesciences Corp

91

$82.10

-$0.57 (-0.689%)

$82.11

$0.01 (0.016%)

3.60/5

Stock Unlock

Stock Profile

Score Card

Good

Insider Transactions

Market News

Form SCHEDULE 13G/A

Filed on 2026-03-26 18:04:17

Form DEFA14A

Filed on 2026-03-26 16:07:42

Form ARS

Filed on 2026-03-26 16:07:14

Form DEFA14A

Filed on 2026-03-26 16:06:11

Form DEF 14A

Filed on 2026-03-26 16:05:48

Form 4

Filed on 2026-03-11 17:15:11

Form 4

Filed on 2026-03-11 17:10:00

Form 144

Filed on 2026-03-11 16:05:26

Form 144

Filed on 2026-03-11 16:02:57

Form 4

Filed on 2026-03-02 17:50:44

Form 4

Filed on 2026-02-26 19:33:53

Form 144

Filed on 2026-02-26 16:08:19

Financials

Price Targets

40.7%

18.7%

-11.4%

Analyst Recommendations

About

Similar Stocks